Your browser is no longer supported. Please, upgrade your browser.
Settings
GHDX Genomic Health, Inc. daily Stock Chart
GHDX [NASD]
Genomic Health, Inc.
Index- P/E56.76 EPS (ttm)1.32 Insider Own0.70% Shs Outstand37.81M Perf Week1.65%
Market Cap2.82B Forward P/E44.64 EPS next Y1.67 Insider Trans-90.94% Shs Float36.37M Perf Month32.84%
Income50.70M PEG2.52 EPS next Q0.37 Inst Own93.70% Short Float4.94% Perf Quarter37.76%
Sales428.80M P/S6.58 EPS this Y725.80% Inst Trans-2.72% Short Ratio2.47 Perf Half Y-10.44%
Book/sh8.54 P/B8.74 EPS next Y12.52% ROA13.80% Target Price70.71 Perf Year43.51%
Cash/sh6.44 P/C11.59 EPS next 5Y22.55% ROE17.90% 52W Range50.77 - 92.18 Perf YTD15.88%
Dividend- P/FCF38.71 EPS past 5Y29.70% ROI8.60% 52W High-19.03% Beta1.01
Dividend %- Quick Ratio5.70 Sales past 5Y8.50% Gross Margin84.60% 52W Low47.02% ATR1.91
Employees829 Current Ratio5.70 Sales Q/Q19.40% Oper. Margin11.30% RSI (14)71.30 Volatility1.96% 2.83%
OptionableYes Debt/Eq0.00 EPS Q/Q83.30% Profit Margin11.70% Rel Volume0.44 Prev Close73.80
ShortableYes LT Debt/Eq0.00 EarningsAug 01 AMC Payout0.00% Avg Volume728.06K Price74.64
Recom3.00 SMA206.95% SMA5022.24% SMA20010.61% Volume323,898 Change1.14%
Jul-29-19Upgrade JP Morgan Underweight → Neutral $60 → $72
Jun-20-19Upgrade Piper Jaffray Neutral → Overweight $72
May-09-19Reiterated Needham Strong Buy $97 → $69
Feb-21-19Reiterated Needham Strong Buy $86 → $97
Jan-03-19Initiated Needham Strong Buy $86
Dec-19-18Initiated Oppenheimer Perform
Oct-23-18Resumed Raymond James Mkt Perform
Jun-13-18Downgrade Ladenburg Thalmann Buy → Neutral
Dec-20-17Downgrade William Blair Outperform → Mkt Perform
Dec-13-17Downgrade JP Morgan Neutral → Underweight
May-03-17Downgrade Raymond James Outperform → Mkt Perform
Jan-18-17Initiated Deutsche Bank Hold $31
Feb-11-16Reiterated Canaccord Genuity Buy $44 → $38
Jan-11-16Downgrade Piper Jaffray Overweight → Neutral
Jan-07-16Reiterated Barclays Underweight $25 → $27
Jan-06-16Upgrade Canaccord Genuity Hold → Buy $26 → $44
Nov-23-15Upgrade UBS Neutral → Buy $29 → $38
Nov-04-15Upgrade Raymond James Mkt Perform → Outperform
Sep-02-15Initiated Barclays Underweight $25
Aug-28-15Upgrade Raymond James Underperform → Mkt Perform
Aug-16-19 05:00PM  URGENT: Monteverde & Associates PC Is Investigating the Following Transaction ACCESSWIRE
01:10PM  A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis Motley Fool
Aug-15-19 11:20AM  CDOR, GHDX, TYPE, and UBNK SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Acquisitions GlobeNewswire
Aug-14-19 12:16PM  Shareholder Investigation Alert: Halper Sadeh LLP is Investigating Whether the Sale of These Companies is Fair to Shareholders UBNK, TYPE, GHDX, NCI GlobeNewswire
09:35AM  Amgen (AMGN) Soars to 52-Week High, Time to Cash Out? Zacks
Aug-12-19 09:15PM  Genomic Health Inc (GHDX) President and CEO Kimberly J Popovits Sold $3.7 million of Shares GuruFocus.com
Aug-09-19 08:00PM  URGENT: Monteverde & Associates PC is Investigating the Following Transaction PR Newswire
Aug-07-19 10:05AM  Genomic Health's Second Quarter Was So Great It Got the Company Acquired Motley Fool
Aug-05-19 06:24PM  Robbins Arroyo LLP: Acquisition of Genomic Health, Inc. (GHDX) by Exact Sciences Corp. (EXAS) May Not Be in Shareholders' Best Interests Business Wire
04:20PM  Here's Why Genetic Testing Stocks Rose as Much as 25.4% in July Motley Fool
10:35AM  Genomic Health, Inc. (GHDX) Shares March Higher, Can It Continue? Zacks
Aug-02-19 06:35PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Genomic Health, Inc. - GHDX ACCESSWIRE
05:18PM  GENOMIC HEALTH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Genomic Health, Inc. - GHDX PR Newswire
11:35AM  Genomic Health (GHDX) to Join Exact Sciences, Posts Q2 Results Zacks
09:23AM  Genomic Health Inc (GHDX) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 07:20PM  Acquisition Boosts Exact Sciences' Role in Cancer Diagnostics GuruFocus.com
12:27PM  Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Acquisitions GlobeNewswire
07:18AM  The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings Benzinga
12:56AM  Investor Rights Alert: Halper Sadeh LLP Reminds Investors That It Is Investigating Whether the Sale of These Companies Is Fair to Shareholders - LTXB, CZR, GHDX ACCESSWIRE
Jul-31-19 03:33PM  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Acquisitions GlobeNewswire
01:38PM  Shareholder Investigation Alert: Halper Sadeh LLP Reminds Investors That it is Investigating Whether the Sale of These Companies is Fair to Shareholders TSS, TYPE, GHDX GlobeNewswire
09:42AM  Pioneering cancer test maker's execs could grab millions in $3 billion buyout American City Business Journals
Jul-30-19 04:55PM  Why Exact Science Made the $2.8 Billion Deal for Genomic Bloomberg
07:27AM  Here's Why Exact Sciences Stock Snapped Right Back Into Place Motley Fool
Jul-29-19 08:00PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc. PR Newswire +6.42%
04:11PM  Merger Fever Runs Hot In Pharma: Viagra, Epipen Sellers Announce Matchup Investor's Business Daily
04:08PM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Genomic Health, Inc. (NASDAQ: GHDX) on Behalf of Genomic Shareholders and Encourages Genomic Investors to Contact the Firm GlobeNewswire
03:01PM  Exact Sciences, Genomic deal will yield greater cancer diagnostic R&D in $20B market American City Business Journals
02:42PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Genomic Health, Inc. to Exact Sciences Corp. is Fair to Shareholders GlobeNewswire
02:37PM  Exact Sciences Stock Breaks Down After Merger Agreement Investopedia
12:26PM  Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Genomic Health, Inc. has obtained a Fair Price in its sale to Exact Sciences Corp. PR Newswire
12:00PM  GENOMIC HEALTH, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger ACCESSWIRE
11:43AM  Why Exact Sciences Is Sinking and Genomic Health Is Rising Motley Fool
10:48AM  Madison's Exact Sciences to buy cancer diagnostic company in $2.8B deal American City Business Journals
10:05AM  Exact Sciences to Buy Genomic Health for About $2.8 Billion Bloomberg
09:03AM  Genomic (GHDX) Alert: Johnson Fistel Investigates Proposed Sale of Genomic Health, Inc.; Are Shareholders Getting a Fair Deal? PR Newswire
08:15AM  Genomic Health (GHDX) Surpasses Q2 Earnings and Revenue Estimates Zacks
08:07AM  Exact Sciences Will Acquire Genomic Health In $2.8B Deal Benzinga
07:32AM  UPDATE 2-Diagnostic company Exact Sciences to buy Genomic Health in $2.8 bln deal Reuters
07:24AM  Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal Reuters
07:23AM  Exact Sciences to combine with Genomic Health in cash and stock deal valued at $2.8 billion MarketWatch
07:01AM  Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance PR Newswire
07:00AM  Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company PR Newswire
05:53AM  Exact Sciences Reaches Deal to Acquire Genomic Health for $2.8 Billion TheStreet.com
02:37AM  [video]Exact Sciences in Talks to Buy Genomic Health - Report TheStreet.com
Jul-27-19 06:52PM  Exact Sciences in advanced talks to buy Genomic Health for $2.8 billion: Bloomberg Reuters
06:47PM  Exact Sciences in advanced talks to buy Genomic Health for $2.8 bln- Bloomberg Reuters
Jul-25-19 10:33AM  Genomic Health (GHDX) to Report Q2 Results: Wall Street Expects Earnings Growth Zacks
08:00AM  Genomic Health to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 1, 2019 PR Newswire
Jul-24-19 05:43PM  Here's Why Genomic Health Jumped Almost 15% Today Motley Fool +14.88%
10:59AM  Is Genomic Health, Inc.'s (NASDAQ:GHDX) CEO Being Overpaid? Simply Wall St.
07:08AM  The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index Benzinga
Jul-23-19 06:17PM  Genomic Health Set to Join S&P SmallCap 600 PR Newswire
Jun-24-19 02:46PM  What You Must Know About Genomic Health, Inc.'s (NASDAQ:GHDX) Financial Health Simply Wall St.
02:43PM  Genomic Health, Inc. (NASDAQ:GHDX): Will The Growth Last? Simply Wall St.
Jun-20-19 01:00PM  German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test PR Newswire
08:20AM  3 Stocks to Buy Ahead of the Next Market Crash Motley Fool
Jun-11-19 04:14PM  Hedge Funds Have Never Been This Bullish On Genomic Health, Inc. (GHDX) Insider Monkey
Jun-06-19 09:31AM  Why Is Genomic Health (GHDX) Down 5% Since Last Earnings Report? Zacks -5.46%
Jun-05-19 10:24AM  Calculating The Intrinsic Value Of Genomic Health, Inc. (NASDAQ:GHDX) Simply Wall St.
Jun-04-19 01:36PM  Here's Why Genetic Testing Stocks Lost as Much as 26.1% in May Motley Fool
Jun-03-19 11:45AM  Secondary Analysis of Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision PR Newswire
08:00AM  Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test in Node-negative Breast Cancer PR Newswire
May-29-19 08:00AM  Genomic Health to Present at the Jefferies 2019 Healthcare Conference PR Newswire
May-23-19 08:15AM  3 Cancer Treatment Stocks to Buy Right Now Motley Fool
May-22-19 02:14PM  The 1 Stock I'd Buy Right Now Motley Fool
May-20-19 09:49AM  7 A-Rated Healthcare Stocks for Industry Expansion InvestorPlace
May-14-19 05:03PM  Edited Transcript of GHDX earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
10:32AM  Genomic Health's Strong Growth Spooks Investors Motley Fool
May-09-19 10:01AM  Were Invitae's Quarterly Results Really That Bad? Motley Fool
07:46AM  These 3 revolutionary genomics companies are changing lives for patients and investors MarketWatch
May-08-19 01:37PM  Here's Why Shares of Genomic Health Dropped Today Motley Fool -11.58%
12:29PM  Genomic Health, Inc. (NASDAQ:GHDX) Delivered A Weaker ROE Than Its Industry Simply Wall St.
08:29AM  Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up Zacks
May-07-19 09:24PM  Genomic Health Inc (GHDX) Q1 2019 Earnings Call Transcript Motley Fool
07:35PM  Genomic Health (GHDX) Q1 Earnings and Revenues Top Estimates Zacks
06:31PM  Genomic Health: 1Q Earnings Snapshot Associated Press
04:05PM  Genomic Health Reports First Quarter 2019 Financial Results and Recent Business Progress PR Newswire
Apr-30-19 08:00AM  Genomic Health to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019 PR Newswire
Apr-29-19 12:11PM  Heres What Hedge Funds Think About Genomic Health, Inc. (GHDX) Insider Monkey
Apr-24-19 10:33AM  Genomic Health (GHDX) Earnings Expected to Grow: Should You Buy? Zacks
Apr-23-19 10:20AM  3 Medical Product Stocks Set to Beat This Earnings Season Zacks
Apr-16-19 04:10PM  3 High-Growth Stocks That Are Just Getting Started Motley Fool
Apr-15-19 02:00PM  Four Companies Could Power The New Genomics ETF ETF Trends
Apr-05-19 11:43AM  Introducing Genomic Health (NASDAQ:GHDX), The Stock That Zoomed 151% In The Last Five Years Simply Wall St.
Apr-01-19 09:33AM  The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink Zacks
09:09AM  Genomic Health's New Positive Data to Boost Test Uptake Zacks
Mar-29-19 10:36AM  4 Small Biotech Stocks Likely to Witness More Upside in 2019 Zacks
Mar-27-19 01:13PM  8 Genomic Testing Stocks That Can Ease the Sting of Theranos InvestorPlace
Mar-25-19 10:55AM  Here's Why You Should Invest in Genomic Health (GHDX) Now Zacks
08:00AM  New Long-term Outcomes Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score® Test PR Newswire
07:10AM  Report: Exploring Fundamental Drivers Behind ON Semiconductor, Pilgrim's Pride, Merck & Co., Healthcare Services Group, Genomic Health, and Spectrum Pharmaceuticals New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-22-19 09:30AM  Why Is Genomic Health (GHDX) Down 4.8% Since Last Earnings Report? Zacks -7.05%
Mar-08-19 10:10AM  Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up Zacks
Mar-01-19 09:39AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4 Zacks
09:33AM  Spectrum (SPPI) Misses Earnings Estimates in Q4, Tops Sales Zacks
Feb-28-19 10:54AM  Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up Zacks
01:02AM  Biocartis Group NV: BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK GlobeNewswire
Feb-27-19 08:25AM  Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues Zacks
Feb-25-19 07:54PM  Invitae: Buy at the High? Motley Fool
Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Popovits Kimberly JPresident and CEOAug 13Option Exercise29.3415,000440,100123,468Aug 14 04:21 PM
Popovits Kimberly JPresident and CEOAug 13Sale74.2125,0001,855,19998,468Aug 14 04:21 PM
Popovits Kimberly JPresident and CEOAug 12Option Exercise29.3425,000733,500133,468Aug 14 04:21 PM
Cole G BradleyCFOAug 12Option Exercise29.3460,0001,760,40098,970Aug 14 04:22 PM
Popovits Kimberly JPresident and CEOAug 12Sale73.3125,0001,832,654108,468Aug 14 04:21 PM
Cole G BradleyCFOAug 12Sale73.3160,0004,398,58838,970Aug 14 04:22 PM
Popovits Kimberly JPresident and CEOAug 09Option Exercise29.3425,000733,500133,468Aug 12 07:08 PM
Popovits Kimberly JPresident and CEOAug 09Sale73.6625,0001,841,542108,468Aug 12 07:08 PM
Vaughn James JChief Commercial OfficerAug 08Option Exercise31.634,500142,34520,917Aug 12 07:08 PM
Popovits Kimberly JPresident and CEOAug 08Option Exercise29.3425,000733,500133,468Aug 12 07:08 PM
Vaughn James JChief Commercial OfficerAug 08Sale73.744,500331,82516,417Aug 12 07:08 PM
Popovits Kimberly JPresident and CEOAug 08Sale73.8525,0001,846,266108,468Aug 12 07:08 PM
Shak StevenChief Scientific OfficerAug 06Sale72.3725,0001,809,33183,795Aug 07 04:53 PM
McEachron KimChief People OfficerAug 05Option Exercise30.1612,103365,00548,575Aug 07 04:54 PM
McEachron KimChief People OfficerAug 05Sale71.5312,103865,72336,472Aug 07 04:54 PM
Shak StevenChief Scientific OfficerAug 05Sale71.2925,0001,782,130108,795Aug 07 04:53 PM
Shak StevenChief Scientific OfficerAug 02Sale72.4325,0001,810,858133,795Aug 05 04:35 PM
Shak StevenChief Scientific OfficerAug 01Sale72.8725,0001,821,784158,795Aug 05 04:35 PM
Cole G BradleyCFOJul 09Option Exercise17.186,471111,17250,441Jul 11 06:13 PM
Cole G BradleyCFOJul 09Sale57.086,471369,38643,970Jul 11 06:13 PM
Shak StevenChief Scientific OfficerJul 09Sale56.5225,0001,412,943183,795Jul 10 07:23 PM
Vaughn James JChief Commercial OfficerJul 08Option Exercise31.124,500140,04020,917Jul 09 04:15 PM
Shak StevenChief Scientific OfficerJul 08Sale57.1025,0001,427,384208,795Jul 10 07:23 PM
Vaughn James JChief Commercial OfficerJul 08Sale57.094,500256,88616,417Jul 09 04:15 PM
McEachron KimChief People OfficerJul 05Option Exercise30.695,335163,73141,807Jul 09 04:13 PM
McEachron KimChief People OfficerJul 05Sale60.015,335320,15136,472Jul 09 04:13 PM
Shak StevenChief Scientific OfficerJun 14Option Exercise31.1210,550328,316244,345Jun 17 06:26 PM
Shak StevenChief Scientific OfficerJun 14Sale51.6610,550545,003233,795Jun 17 06:26 PM
Shak StevenChief Scientific OfficerJun 13Option Exercise31.1225,000778,000258,795Jun 17 06:26 PM
Shak StevenChief Scientific OfficerJun 13Sale51.9425,0001,298,572233,795Jun 17 06:26 PM
Shak StevenChief Scientific OfficerJun 12Option Exercise30.9525,000773,768258,479Jun 13 07:33 PM
Shak StevenChief Scientific OfficerJun 12Sale51.3425,0001,283,478233,479Jun 13 07:33 PM
Cole G BradleyCFOJun 11Option Exercise17.185,00085,90048,722Jun 13 07:31 PM
Shak StevenChief Scientific OfficerJun 11Option Exercise30.8925,000772,278258,479Jun 13 07:33 PM
Shak StevenChief Scientific OfficerJun 11Sale51.4325,0001,285,702233,479Jun 13 07:33 PM
Cole G BradleyCFOJun 11Sale51.465,000257,28143,722Jun 13 07:31 PM
Vaughn James JChief Commercial OfficerJun 06Option Exercise31.124,500140,04024,920Jun 10 07:37 PM
Vaughn James JChief Commercial OfficerJun 06Sale52.478,745458,82916,175Jun 10 07:37 PM
Cole G BradleyCFOMay 14Option Exercise20.4411,424233,52450,146May 15 04:55 PM
Cole G BradleyCFOMay 14Sale57.1711,424653,15243,722May 15 04:55 PM
Vaughn James JChief Commercial OfficerMay 08Option Exercise31.124,500140,04027,664May 10 08:10 PM
Shak StevenChief Scientific OfficerMay 08Sale57.9025,0001,447,616233,479May 10 08:07 PM
Vaughn James JChief Commercial OfficerMay 08Sale58.087,244420,73020,420May 10 08:10 PM
BAKER BROS. ADVISORS LPDirectorApr 12Sale65.30287,46518,770,15349,904Apr 12 05:01 PM
BAKER BROS. ADVISORS LPDirectorApr 12Sale65.3211,204731,88949,893Apr 12 05:02 PM
BAKER BROS. ADVISORS LPDirectorApr 11Sale66.90202,28113,533,25350,180Apr 12 05:01 PM
BAKER BROS. ADVISORS LPDirectorApr 10Sale69.1213,146908,68450,375Apr 10 05:24 PM
BAKER BROS. ADVISORS LPDirectorApr 10Sale68.70124,5428,556,11050,388Apr 10 05:24 PM
Cole G BradleyCFOApr 09Option Exercise21.0515,000315,70058,722Apr 11 06:11 PM
BAKER BROS. ADVISORS LPDirectorApr 09Sale67.7021,0631,425,88550,508Apr 10 05:24 PM
Cole G BradleyCFOApr 09Sale67.6115,0001,014,12043,722Apr 11 06:11 PM
Vaughn James JChief Commercial OfficerApr 08Option Exercise31.123,00093,36026,164Apr 10 07:48 PM
Popovits Kimberly JPresident and CEOApr 08Sale66.9310,000669,321108,952Apr 10 07:45 PM
Vaughn James JChief Commercial OfficerApr 08Sale67.733,000203,17923,164Apr 10 07:48 PM
BAKER BROS. ADVISORS LPDirectorApr 08Sale67.9022,6481,537,72050,528Apr 10 05:24 PM
BAKER BROS. ADVISORS LPDirectorApr 05Sale68.6977,6485,333,39750,550Apr 05 05:51 PM
BAKER BROS. ADVISORS LPDirectorApr 04Sale66.6481,0535,401,33950,625Apr 05 05:51 PM
BAKER BROS. ADVISORS LPDirectorApr 03Sale68.9097,2696,701,71750,703Apr 05 05:51 PM
Shak StevenChief Scientific OfficerApr 01Sale67.7625,0001,694,059258,479Apr 01 06:58 PM
Shak StevenChief Scientific OfficerMar 29Sale69.3825,0001,734,470283,479Apr 01 06:58 PM
Shak StevenChief Scientific OfficerMar 28Sale68.5325,0001,713,259308,479Apr 01 06:58 PM
BAKER BROS. ADVISORS LPDirectorMar 21Sale74.7156,6514,232,16450,498Mar 25 05:05 PM
Pla FredericCOOMar 19Option Exercise28.774,700135,23436,275Mar 19 06:42 PM
BAKER BROS. ADVISORS LPDirectorMar 19Sale74.63105,1267,845,64850,601Mar 19 05:31 PM
BAKER BROS. ADVISORS LPDirectorMar 19Sale74.3450,1003,724,59450,553Mar 19 05:37 PM
BAKER BROS. ADVISORS LPDirectorMar 19Sale74.3450,1003,724,59450,553Mar 19 05:48 PM
Pla FredericCOOMar 19Sale75.004,700352,50031,575Mar 19 06:42 PM
Pla FredericCOOMar 18Option Exercise27.481,00027,48032,575Mar 19 06:42 PM
BAKER BROS. ADVISORS LPDirectorMar 18Sale74.19109,5338,125,96850,702Mar 19 05:31 PM
Pla FredericCOOMar 18Sale75.121,00075,12231,575Mar 19 06:42 PM
BAKER BROS. ADVISORS LPDirectorMar 15Sale74.6455,3474,131,08850,808Mar 19 05:31 PM
BAKER BROS. ADVISORS LPDirectorMar 14Sale76.4965,0944,978,78750,861Mar 14 05:03 PM
BAKER BROS. ADVISORS LPDirectorMar 13Sale75.9280,2536,092,92350,924Mar 14 05:03 PM
Cole G BradleyCFOMar 12Option Exercise21.0515,000315,70058,722Mar 14 04:06 PM
BAKER BROS. ADVISORS LPDirectorMar 12Sale75.6374,1805,610,24851,001Mar 14 05:03 PM
Cole G BradleyCFOMar 12Sale75.1515,0001,127,27343,722Mar 14 04:06 PM
BAKER BROS. ADVISORS LPDirectorMar 11Sale75.0049,0353,677,48451,072Mar 11 04:59 PM
Popovits Kimberly JPresident and CEOMar 08Sale73.2210,000732,237125,952Mar 12 09:47 PM
BAKER BROS. ADVISORS LPDirectorMar 08Sale73.5522,7001,669,51951,119Mar 11 04:59 PM
Vaughn James JChief Commercial OfficerMar 07Option Exercise31.123,00093,36025,790Mar 11 06:42 PM
BAKER BROS. ADVISORS LPDirectorMar 07Sale73.722,000147,44551,141Mar 11 04:59 PM
Vaughn James JChief Commercial OfficerMar 07Sale73.873,000221,59622,790Mar 11 06:42 PM
BAKER BROS. ADVISORS LPDirectorMar 05Sale77.0410,300793,50451,143Mar 05 06:30 PM
Shak StevenChief Scientific OfficerMar 04Option Exercise28.057,500210,375342,979Mar 05 04:17 PM
Shak StevenChief Scientific OfficerMar 04Sale75.897,500569,202335,479Mar 05 04:17 PM
BAKER BROS. ADVISORS LPDirectorMar 04Sale76.4927,8112,127,24951,153Mar 05 06:30 PM
Shak StevenChief Scientific OfficerMar 01Option Exercise28.0525,000701,250360,479Mar 05 04:17 PM
Shak StevenChief Scientific OfficerMar 01Sale77.2225,0001,930,424335,479Mar 05 04:17 PM
BAKER BROS. ADVISORS LPDirectorMar 01Sale77.2079,2766,120,38751,180Mar 05 06:30 PM
Shak StevenChief Scientific OfficerFeb 28Option Exercise19.3525,000483,850360,479Mar 01 07:05 PM
BAKER BROS. ADVISORS LPDirectorFeb 28Sale76.2060045,71951,256Feb 28 06:22 PM
Shak StevenChief Scientific OfficerFeb 28Sale76.4025,0001,909,972335,479Mar 01 07:05 PM
Shak StevenChief Scientific OfficerFeb 27Option Exercise17.1825,000429,500360,479Mar 01 07:05 PM
Shak StevenChief Scientific OfficerFeb 27Sale76.5925,0001,914,824335,479Mar 01 07:05 PM
BAKER BROS. ADVISORS LPDirectorFeb 27Sale76.6539,1092,997,79251,257Feb 28 06:21 PM
BAKER BROS. ADVISORS LPDirectorFeb 26Option Exercise17.5916,500290,2359,100,815Feb 28 06:21 PM
BAKER BROS. ADVISORS LPDirectorFeb 26Sale78.118,650675,61451,295Feb 28 06:21 PM
FUCHS HENRY JDirectorFeb 25Option Exercise27.753,52197,7089,853Feb 26 04:51 PM
FUCHS HENRY JDirectorFeb 25Sale79.023,521278,2266,332Feb 26 04:51 PM
Cohen Fred EDirectorFeb 22Option Exercise26.0110,000260,10077,619Feb 26 04:49 PM